A new regulatory mechanism for Raf kinase activation, retinoic acid-bound Crabp1

Sung Wook Park1, Jennifer Nhieu1, Shawna D. Persaud1, Michelle C. Miller2, Youlin Xia3, Yi-Wei Lin1, Yu-Lung Lin1, Hiroyuki Kagechika4, Kevin H. Mayo2 & Li-Na Wei1

The rapidly accelerated fibrosarcoma (Raf) kinase is canonically activated by growth factors that regulate multiple cellular processes. In this kinase cascade Raf activation ultimately results in extracellular regulated kinase 1/2 (Erk1/2) activation, which requires Ras binding to the Ras binding domain (RBD) of Raf. We recently reported that all-trans retinoic acid (atRA) rapidly (within minutes) activates Erk1/2 to modulate cell cycle progression in stem cells, which is mediated by cellular retinoic acid binding protein 1 (Crabp1). But how atRA-bound Crabp1 regulated Erk1/2 activity remained unclear. We now report Raf kinase as the direct target of atRA-Crabp1. Molecularly, Crabp1 acts as a novel atRA-inducible scaffold protein for Raf/Mek/Erk in cells without growth factor stimulation. However, Crabp1 can also compete with Ras for direct interaction with the RBD of Raf, thereby negatively modulating growth factor-stimulated Raf activation, which can be enhanced by atRA binding to Crabp1. NMR heteronuclear single quantum coherence (HSQC) analyses reveal the 6-strand β-sheet face of Crabp1 as its Raf-interaction surface. We identify a new atRA-mimicking and Crabp1-selective compound, C3, that can also elicit such an activity. This study uncovers a new signal crosstalk between endocrine (atRA-Crabp1) and growth factor (Ras-Raf) pathways, providing evidence for atRA-Crabp1 as a novel modulator of cell growth. The study also suggests a new therapeutic strategy by employing Crabp1-selective compounds to dampen growth factor stimulation while circumventing RAR-mediated retinoid toxicity.

All-trans retinoic acid (RA), an active metabolite of vitamin A, regulates various physiological processes such as organ development, vision, cellular growth, differentiation, immune system regulation, and apoptosis, etc. These processes are mainly mediated by nuclear RA receptors (RARs), which are ligand-dependent transcription factors that regulate the expression of numerous target genes in various cell types1–4.

Recently, increasing attention has been directed towards non-canonical activity of atRA, independent of its ability to regulate gene expression via nuclear RARs. Other potential cytosolic activity of atRA has also been reported. For instance, RARs can sometimes be localized outside the nuclei, becoming cytosolic or on plasma membrane, to activate several kinases including p38 mitogen activated protein kinase (MAPK), PI3 kinase, and extracellular-signal-regulated kinase 1/2 (Erk1/2)5–7. We have reported that atRA can rapidly activate Erk1/2 activity8,9, and determined a physiological relevance for this “non-canonical” activity of atRA in cell cycle control of stem cells such as embryonic stem cells (ESCs) and neuron stem cells (NSCs)8,10. In ESCs, atRA can very rapidly (within minutes) activate Erk1/2 in an RAR- and membrane signal-independent manner8. By using gene-knockout systems, we have unambiguously determined that cellular retinoic acid binding protein 1 (Crabp1) mediates the non-canonical (non-genomic) activity of atRA in regulating Erk1/2, ultimately reflected on altered cell cycle control of ESCs8 and expansion of NSC pool in hippocampus that affects mouse learning behavior10. However, how Crabp1 mediates the non-canonical activity of atRA to modulate Erk1/2 activation remains entirely unclear.

1Department of Pharmacology, University of Minnesota, Minneapolis, MN, 55455, USA. 2Department of Biochemistry, Molecular Biology & Biophysics, University of Minnesota, Minneapolis, MN, 55455, USA. 3Minnesota NMR Center, University of Minnesota, Twin Cities, Minneapolis, Minnesota, 55455, USA. 4Tokyo Medical and Dental University, Institute of Biomaterials and Bioengineering, Tokyo, Japan. Sung Wook Park, Jennifer Nhieu, Shawna D. Persaud and Michelle C. Miller contributed equally. Correspondence and requests for materials should be addressed to L.-N.W. (email: weixx009@umn.edu)
Erk kinases participate in numerous biological processes and can be regulated by various signal inputs. Classical (canonical) Erk signaling begins with stimulation on the cell surface by growth factors binding to receptor tyrosine kinases (e.g. epidermal growth factor receptor), leading to activation of Ras GTPase. The activated Ras (GTP-bound) binds to the Ras binding domain (RBD) of the rapidly accelerated fibrosarcoma (Raf) kinase which then undergoes a conformational change leading to its enzymatic activation. Raf activation is the first critical step in the growth signaling cascade. Activated Raf then phosphorylates MAPK-Erk kinase 1/2 (MeK1/2), and finally MeK1/2 phosphorylates Erk1/2. Erk/MAPK signal strength and duration can be regulated by multiple mechanisms including Ras and Raf mutations, interactions with scaffold proteins, and crosstalk with other signaling components such as cAMP-protein kinase A and Ca²⁺-calcineurin, etc.

However, it is unclear which component(s) in the Raf-Mek-Erk1/2 signaling cascade is/are targeted by Crabp1.

Here we report Raf kinase as the direct target of atRA-Crabp1 and determine the molecular mechanism of Crabp1’s action, which occurs through direct interaction with the RBD of Raf kinase. Using NMR, we describe the interaction surface on Crabp1 proposed to interact with the RBD of Raf. Finally, we identify a Crabp1-selective, atRA-mimicking compound which can also modulate Raf activation in a Crabp1-dependent manner. The physiological significance of this new finding is discussed in the context of signal cross-talk between the erucogene/vitamin A and growth factors, which is key to homeostatic control for cell growth and differentiation.

Results
Crabp1 sequentially forms complexes with components of the Raf-Mek-Erk signaling pathway to modulate Erk1/2 phosphorylation. We have previously reported membrane signal- and nuclear RAR-independent atRA-regulated Erk1/2 activation in a stem cell context, which requires Crabp1. By screening known signaling components, we found that Crabp1 forms atRA-enhanced complexes with Raf-Mek signal-

Components in ESCs. Figure 1A shows a Duolink proximity ligation assay for the real-time, sequential molecular scaffold formation of endogenous Crabp1 with the Raf-Mek-Erk signaling components, i.e., Crabp1-Raf/Mek/Erk in ESCs at different time points following atRA treatment (100 nM). The top panel shows that Crabp1 first associates with cRaf within 10 min of atRA treatment and the association sustains for 60 min. Subsequently, cRaf/Crabp1 forms complexes with MeK1/2 and p-Erk1/2 (the middle and lower panels, respectively). The kinetics of forming these Crabp1-containing molecular scaffolds indicate that these events occur sequentially (Fig. 1B), initiated as early as 10 min of atRA addition, and peaked at 15 min. Furthermore, co-immunoprecipitation demonstrates that Crabp1 forms stable complexes with cRaf, MeK2 and Erk1/2 in the presence of atRA (Fig. 1C, comparing lanes 2 and 3). These data suggest that Crabp1 may serve as a signal scaffold, or allosteric regulator, of Raf, conveying Raf to Mek and Erk activation by forming an atRA-inducible signalosome activating the final target kinase, Erk1/2.

To determine whether Raf indeed is the immediate and direct target of atRA-Crabp1, we employed in vitro kinase assay for Raf using its direct substrate, MeK1. Figure 1D shows that Crabp1 is indeed involved in Raf-mediated MeK1 phosphorylation. In this in vitro kinase assay, atRA alone, without growth factor stimulation, has no effect on Raf activity (MeK1 phosphorylation; the 2nd lane). In the presence of Crabp1, atRA can increase Raf activity (comparing the 3rd and 4th lanes). Thus, without growth factor input, atRA-Crabp1 alone is able to activate Raf and then MeK1. We further validated the requirement for Crabp1 in this non-canonical Raf/Mek activation in a physiologically relevant cellular context such as ESC. Figure 1E shows the comparison between wild-type (WT) and Crabp1-null (KO) ESCs treated with atRA, without growth factor input, for 30 min. The data show that cRaf phosphorylation at S338 (p-S338), which is a critical residue for priming its full activation, is elevated by atRA in the absence of growth factor only in WT ESCs (top, left), but not in KO ESCs (top, right). Consistently, atRA-induced Erk1/2 phosphorylation is also detected only in WT ESCs, but not in KO ESCs (top 3rd panel). We then tested whether Crabp1, as a scaffold without growth factor input, can facilitate Raf-Mek-Erk activation by comparing Crabp1-negative and Crabp1-expressing HEK293T cells (Fig. 1F). As shown, atRA alone (without Crabp1, for 15 min) does not activate cRaf (p-S338), MeK1/2 and Erk1/2 (comparing lanes 1 and 2). Crabp1 alone (without atRA) also has little effect (lane 3). But atRA with Crabp1 (atRA-Crabp1) increases p-S338, peaking at 30 min (lane 5), and reduces p-S259, a mark of inactive cRaf, which seems to partially recover at a longer duration of treatment (60 min, the 2nd panel; lanes 3–6). Consistently, phosphorylation of MeK1/2 and Erk1/2 peaks at 15 min of atRA treatment (lane 4), and tapers afterward (the 4th and 6th panels).

We then examined the relationship between Crabp1 and the well-known scaffolding protein kinase suppressor of Ras (Ksr1). Figure 1G shows that atRA reduces cRaf association with Ksr1, but increases cRaf association with Crabp1, suggesting competition between Ksr1 and Crabp1 for association with cRaf.

Together, these results show that Crabp1 is a new scaffold, or allosteric regulator, of Raf-Mek-Erk signaling complex. In the absence of growth factor stimulation, Crabp1 can mediate the non-canonical activity of atRA to activate Raf.

atRA-Crabp1 dampens EGF-induced Erk1/2 activation. To examine how atRA-Crabp1 signaling impacts on the growth factor mediated MAPK signaling, we determined the effect of atRA-Crabp1 on the receptor tyrosine kinase (RTK)-activation of Erk, stimulated by epidermal growth factor (EGF), in WT and KO ESCs. The data show that atRA treatment alone (without EGF stimulation) rapidly increases Erk1/2 phosphorylation only in WT ESCs, but not in KO ESCs, at an intensity apparently lower than that of EGF stimulation (25 ng/mL, 5 minutes). Importantly, pre-treatment with atRA before EGF stimulation in ESCs results in dampened Erk1/2 phosphorylation, as compared to Erk1/2 activation induced by EGF alone (Fig. 2A). This result indicates that while atRA-Crabp1 by itself can activate Erk1/2 under the basal condition without growth factor stimulation, atRA-Crabp1 in fact can negatively modulate (dampen) canonical, growth factor-activated Erk1/2.

It is known that Ras activation by RTKs on membrane initiates Raf/Erk signaling pathway, and mutations of Ras isoforms such as G12V of HRas occur as constitutive activators in 20–30% of various tumors. Further, these
Figure 1. Crabp1 sequentially forms complexes with the components of Raf-Mek signaling pathway to modulate Erk1/2 phosphorylation. (A) PLA (Duolink) assays detect atRA-induced sequential formation of Crabp1, first with cRaf (top panel), then Mek1/2 (middle panel) and finally p-Erk1/2 (bottom panel). Nuclei are stained with DAPI. The red punctate represents complex formed with Crabp1. Representative microphotographs of various fields are shown, and scale bar refers to 20 μm. (B) Quantitation of PLA signals. The kinetics of Crabp1 forming complexes with the three key components in the MAPK pathway are plotted for relative numbers of PLA signal/cell each with a standard deviation. Experiments were performed three times. (C) Crabp1 is a scaffold protein for cRaf-Mek2-Erk1/2, and atRA induces scaffolding. HEK293T cells expressing Flag-Crabp1-HA were treated with 100 nM atRA for 15 min, and lysates were immunoprecipitated with M2 flag beads. WT cells were used as negative control. Inp refers to input control. (D) Semi in vitro kinase assay. Recombinant Mek1 is phosphorylated by TnT generated HA-cRaf and ATP in the absence or presence of His-Crabp1. Phosphorylation is increased by the addition of 100 nM atRA. Densitometric analyses western blot for lanes 3 and 4 are depicted at right (*P < 0.05, student t-test). (E) WT (C7) and CKO ESCs were treated with 100 nM atRA for 30 min, and relevant endogenous proteins in cell lysates were monitored. WT and Flag-Crabp1-HA-expressing HEK293T cells were treated with atRA for the indicated time, and relevant endogenous proteins in cell lysates were monitored via western blot. (F) Crabp1 competes with Ksr1. Lysates of HEK293T expressing Flag-Crabp1-HA were treated with 100 nM atRA for 15 min followed by immunoprecipitation with anti-cMyc antibody and western blot analysis. Relative intensity is numerically marked.
Figure 2. atRA/ Crabp1 dampens canonical EGF and Ras mutation elicited Erk1/2 activation. (A) Dampening effects in ESCs. ESCs were pre-treated with atRA (100 nM, 30 min) and then with EGF (25 ng/ml, 5 min). Erk1/2 phosphorylation, the final signal of MAPK cascade, is shown (top panel). Blots are representatives of three independent experiments. Band intensity is statistically analyzed at bottom: *P < 0.01, **P < 0.001 and ***P < 0.005 (n = 4). (B, C) Dampening effects in Crabp1-positive HEK293T clones over-expressing other components as indicated, treated with, or without, atRA for 30 min. Anti-Flag antibody recognizes Flag-tagged Ras and Crabp1. (B) Phosphorylation of cRaf (at S338) and Erk1/2 was dampened by atRA in cells harboring the constitutively active mutant HRas (G12V), *P < 0.05 (n = 4). (C) Ras interaction with Raf (indicating activated Ras) in cells, monitored using GST-Raf-RBD beads (Millipore Sigma) to pulldown cell lysates in (B). The active Ras bound to the RBD of Raf is monitored. RBD: Ras binding domain. *P < 0.05 (n = 3).

apparently reduced (lane 5). These results indicate that atRA-Crabp1 can inhibit active Ras-induce Raf phosphorylation, implicating that atRA-Crabp1 may compete with the active Ras for Raf interaction.

Crabp1 competes with Ras for direct interaction with Raf. We thus extended our hypothesis that, Crabp1 may directly compete with the active Ras for Raf activation. We first determined the molecular basis of how atRA-Crabp1 intersected the canonical Raf signaling pathway using an in vitro protein interaction assay. Figure 3A shows that Crabp1 indeed directly interacts with Raf (both BRaf and cRaf tested here); further, the interaction is enhanced by atRA. We then used this type of in vitro direct protein interaction assay to dissect the interaction motif. Figure 3B shows that Crabp1 directly interacts with the regulatory domain of cRaf, particularly the RBD, which is also enhanced by atRA. As the RBD is highly conserved across all three Raf members (A, B and C)22, Crabp1 may directly compete with the active Ras for Raf activation. We first determined the molecular basis of Crabp1 indeed directly interacts with Raf (both BRaf and cRaf tested here); further, the

Figure 3C shows that Crabp1 (the active form) is used (the 4th and 5th lanes), Raf interaction with Crabp1 is enhanced by atRA (lane 3). Importantly, when the oncogenic G12V mutant Ras (the active form) is used (the 4th and 5th lanes), Raf preferentially interacts with Crabp1 in the absence of atRA (the 4th lane), but adding atRA to the reaction enables Crabp1 to effectively compete with the active Ras (the 5th lane). By altering Crabp1 and atRA inputs, it is clear that atRA-Crabp1 competes with Ras-G12V in a Crabp1 (Fig. 3D) and atRA (Fig. 3E) dose-dependent manner. These in vitro studies clearly validate the competition of atRA-Crabp1 with the active Ras in forming complexes with Raf.

Finally, we examined the competition between atRA-Crabp1 and active Ras that underlies atRA's ability to dampen Raf activation (phosphorylation) in cells using the reconstituted HEK293T cells and monitored Raf activation directly by its S338 phosphorylation. Figure 3F shows that, in the absence of Crabp1 (lanes 2–4), atRA has no effects on Ras-G12V-triggered Raf activation (no change in pS338 level, the top panel). However, in the
Figure 3. Crabp1 directly interacts with the RBD of Raf and competes with Ras for interaction with the RBD. (A) Direct protein interaction assay. TnT generated HA-BRaf or HA-cRaf, together with the purified His-Crabp1, was precipitated with anti-HA antibody, and its binding partner His-Crabp1 was detected by anti-His antibody. NS refers to a non-specific band. (B) Mapping the Crabp1-interacting domain of Raf. The constructs of regulatory domain (His-c-Raf-(R)) and RBD (GST-Raf-RBD) (Cytoskeleton Inc) used for protein interaction assay are depicted (top). CRD: cysteine rich domain. Ni/NTA beads capturing His-cRF-(R) or GST-Raf-RBD beads were used to pull down cell lysates containing Flag-HA-Crabp1. Anti-Flag antibody detects increased binding of Flag-Crabp1 to the RBD by RA (bottom). (C) Crabp1 competes with active Ras for Raf interaction. TnT-generated Flag-HRas (WT or G12V) and cell lysates containing Flag-HA-Crabp1 were pulled down by His-cRF-(R) with or without atRA. Crabp1 was detected by anti-HA antibody, and Ras by anti-Flag antibody from the cut upper region. EV: empty vector. (D) Crabp1 dose-dependent effect in competing with the activated Ras. Increasing amount of Flag-HA-Crabp1 was mixed with the activated HRas (G12V) and pulled down with GST-Raf-RBD (Millipore Sigma) in the presence of atRA. Anti-Flag antibody detected HRas and Crabp1 on the same membrane. (E) atRA dose-dependent effect on Crabp1 competition with the active Ras. Active HRas (G12V) was incubated with increasing concentrations of atRA in the absence or presence of Flag-HA-Crabp1 and pulled down with GST-Raf-RBD beads (Cytoskeleton Inc). The pull-down products were detected by western blots with the indicated antibodies from the different membranes. (F) Direct assay of Raf activation (293T clone) observed with HA-cRF-(S338) treated with or without Crabp1. All blots are representatives of three independent experiments and relative fold intensity is numerically marked.

...presence of Crabp1 (lanes 5–7) atRA, dose-dependently, dampens Ras-G12V-triggered Raf activation (lowered pS338 levels). These in-cell results validate our conclusion that atRA-Crabp1 competes with active Ras for Raf activation, which underlines the dampening effect of atRA on growth factor-activated Raf-Erk signaling. The competition of Crabp1 with Ras is mediated by its direct interaction with the RBD of Raf, which is also the critical contact domain for Ras.

**Structural validation of Crabp1-Raf interaction.** To evaluate the molecular feature of Crabp1 interaction with the RBD of Raf, we then employed NMR analyses to identify the interaction surface on Crabp1. Molecular and structural changes of Crabp1 have been examined in the past mainly with respect to atRA-induced conformational changes, especially the atRA-binding pocket. The molecular changes in its surface areas, as well as whether/how Crabp1 may interact with other molecules were never addressed. To substantiate our finding that Crabp1 can directly interact with the RBD of Raf, we thus employed NMR spectroscopy to determine the molecular features of Crabp1 complex formation with the RBD of Raf. Consistent with previous reports, our NMR studies demonstrate that Crabp1 binds atRA18–22. Figure 4A,B show 15N-1H HSQC spectral expansions of 15N-labeled Crabp1 in the absence of atRA (black peaks) overlaid with those of Crabp1 in the presence of atRA (red peaks). Interactions occur within the slow exchange regime on the chemical shift time scale22, which together with the observed large chemical shift changes (Fig. 4C) indicate that atRA binds to Crabp1 relatively strongly ($K_{\text{d}} < 1\,\mu M$) within the Crabp1 β-sandwich as previously reported26,27. Figure 4C plots maximal chemical shift changes vs. the Crabp1 amino acid sequence and indicates where atRA binds to Crabp1. The most perturbed...
residues indicate that atRA binds within the Crabp1 β-sandwich, as previously reported. We also note that several resonances that interact with atRA are not observed in apo-Crabp1, and that these resonances become well defined upon atRA binding. Rizo et al. previously proposed that residues around the atRA binding site in apo-Crabp1 are dynamic and not observed due to exchange broadening.

More importantly, our NMR data demonstrate that cRaf RBD interacts with Crabp1 in solution. Figure 5A overlays 15N-1H HSQC spectral expansions of 15N-labeled Crabp1 (19 µM) in the absence (black peaks) and presence (red peaks) of cRaf at 126 µM. The observation that Crabp1 resonances are significantly shifted upon addition of cRaf indicates that cRaf indeed binds to Crabp1. The same effects are essentially observed in the presence of atRA. In fact, as a function of c-Raf concentration, Crabp1 chemical shift changes of three of the most shifted atRA-bound Crabp1 resonances allow us to roughly estimate a KD ~ 40 µM (Fig. 5B). Figure 5C,D plot chemical shift (Δδ) and resonance intensity (ΔIntensity) changes, respectively, vs. the Crabp1 amino acid sequence. Overall, the most perturbed residues are color highlighted (red for (Δδ > 2 SD) from the average; orange for (Δδ between 1 SD and 2 SD), and cyan for (Δδ < 1 SD) on a crystal structure of Crabp1 (PDB 1CBR, Fig. 5E). This analysis indicates that the most likely region for cRaf interactions is within the 6-strand β-sheet face of Crabp1. Although some effects are noted on the opposing face of the β-sandwich, these effects are likely to be indirect. This in turn suggests that Raf binding may allosterically affect Crabp1 structure/dynamics throughout other parts of Crabp1.

Crabp1-selective compound C3 dampens growth factor-stimulated Raf activation. atRA is not an ideal therapeutic agent because it binds to and acts on a wide spectrum of biological molecules including all RARs. In a biological screening for Crabp1-selective, RAR-independent atRA-analogs, we have previously identified compound 3 (C3) with a chemical formula of C17H16NO3Cl, which can bind Crabp1 to activate Erk1/2 phosphorylation without eliciting genomic (RAR-mediated) effects. We thus examined whether C3 could enhance Crabp1 competition with active Ras using in vitro direct interaction assays. Figure 6A shows that C3 indeed increases Crabp1 binding to the RBD of Raf dose-dependently. Further competition assay using oncogenic HRas-G12V mutant shows that C3-Crabp1 competes with the activated Ras also in a C3 dose-dependent manner (Fig. 6B). To further validate this mechanism in a cellular context, we used HEK293T cell clones reconstituted...
**Figure 5.** NMR analyses showing Crabp1 direct interaction with the RBD of cRaf. (A) An expanded region of $^{1}H,^{15}N$ HSQC spectra of the 19µM Crabp1 in the absence (black peaks) and presence (red peaks) of 126µM cRaf-(R) (aa 51–187). (B) Titration curves of selected Crabp1 residues (C96, T97, Q98) in which the chemical shift change is plotted vs. the cRaf-(R) concentration. (C) Maximal chemical shift changes ($\Delta \delta$) induced by cRaf-(R) on Crabp1. (D) Maximal resonance intensity changes ($\Delta$Intensity) induced by cRaf-(R) on Crabp1. (E) Cartoon representation of cRaf-(R) interaction sites with marked spectral changes on Crabp1 in the presence of cRaf-(R): 1 SD – orange, 2SD – red. PDB: 1CBR. Chemical shifts were internally referenced to DSS (4,4-dimethyl-4-silapentane-1-sulfonic acid), and chemical shift differences in panels (C,D) were calculated as $[(\Delta \delta ^{1}H)^{2} + (0.25 \Delta \delta ^{15}N)^{2}]^{1/2}$. NMR acquisition and sample conditions are described in the "Materials and Methods".

**Figure 6.** Crabp1-selective compound C3 enhances Crabp1 interaction with the Raf-RBD and competition with active Ras for RBD binding. (A) In vitro interaction assay. Compound C3 increases Crabp1 interaction with the Raf-RBD. (B) Compound C3/Crabp1 reduces active Ras interaction with the Raf-RBD. (C) HEK293T cells reconstituted with the indicated expression vectors and treated with, or without, C3 for 30 min were monitored for Raf activation in cells, indicated with p-cRaf (S338).
with cRaf and the activated Hras (G12V) in the absence of growth factors (Fig. 6C). The data show that C3 indeed dampens cRaf phosphorylation at S338 only in the presence of Crabp1 (top, right two lanes), confirming that C3, like atRA, also effectively dampens Raf-Mek-Erk activation via Crabp1 in cells. However, C3 at higher concentration (5 µM) seems to exhibit cytotoxicity in cells (data not shown).

Discussion

The classical/canonical MAPK signaling begins with receptor tyrosine kinase activation on the cell membrane and propagates through Ras-Raf-Mek-Erk for various biological processes such as cell proliferation, cell cycle regulation, cell survival and apoptosis, etc. In a cancer context, the MAPK pathway has a well-documented role in contributing to disease progression and metastasis. Therefore, multiple components of this signaling pathway provide attractive therapeutic targets for cancers. However, current attempts to target MAPK components have yielded little success, highlighting a need for novel therapeutic strategies.

We and others have shown that atRA, a primarily differentiating agent that is known to act via its nuclear receptors (RARs), can also crosstalk with this MAPK signaling to rapidly stimulate or suppress Erk phosphorylation in various cellular contexts. We have shown, in the physiologically relevant system of ESC culture, that atRA modulates Erk activation in a bi-phasic manner. First is a rapid activation (within minutes), which is followed by a delayed activation (after 6–12 hrs). The first rapid activation of Erk by atRA was RAR-independent, which led us to propose a non-canonical atRA signaling pathway now recognized to be mediated by Crabp1. Importantly, this newly established Crabp1-dependent signaling pathway of atRA can modulate cell cycle of ESC in cultures and NSC pool expansion in the hippocampus. It is increasingly clear that Crabp1-mediated signaling is physiologically relevant and significant. This current study demonstrates, for the first time, how Crabp1 functions at the molecular level, further supporting the biological significance of this non-canonical, RAR-independent, activity of atRA. With respect to the regulation of growth factor-stimulated MAPK signaling, it is most exciting to find that atRA-Crabp1 directly targets Raf, given Raf kinase is a highly desirable therapeutic target in diseases such as cancer.

In a physiological context, two potential effects of atRA/Crabp1 on MAPK signaling occur, either weak activation of Erk1/2 in the absence of EGF or dampening EGF-stimulated Erk1/2 activation (model in Fig. 7). The contextual dependency of holon-Crabp1 functions is consistent with most of the previous observations that atRA can either activate or suppress Erk activity, depending on cell types and culture conditions. This also suggests a need for careful evaluation of future studies conducted in different types of cells and/or in various culture conditions.

This non-canonical signaling pathway of atRA in conjunction with MAPK pathway also suggests a novel paradigm for signal crosstalk between the endocrine and growth factor axes (Fig. 7). Proliferating cells (such as normal stem cells) may be exposed to different growth factors for continuous proliferation and/or differentiating signals such as atRA that canonically activates nuclear programs to alter gene expression for cellular differentiation. Then cells can either proliferate normally (when atRA is absent or low and growth factors are available) or prepare for differentiation (when atRA concentration is elevated and/or growth factors are withdrawn). In this context, signaling in the endocrine axis can orchestrate or modulate the cellular response to growth factors. Therefore, the non-canonical pathway where atRA-Crabp1 competes with active Ras for Raf interaction, thereby dampening EGF/EGFR-Ras signaling and rendering only weak phosphorylation of Erk1/2 in spite of EGF stimulation.
latter situation (atRA present, prime for differentiation), cell proliferation must first decrease. This decrease could be facilitated by the initial non-genomic action of atRA to dampen growth factor sensitivity. Indeed, our previous study has found that this atRA-Crabp1 mediated Erk signaling slowed down cell cycle progression. This will better prepare cells for differentiation typically mediated by the delayed RAR-dependent genomic action of atRA. Over all, the Crabp1-mediated crosstalk may represent a delicate cellular program required for coordinating the nuclear and extra-nuclear environments when an important decision, such as proliferation vs. differentiation, has to be made.

From a therapeutic point of view, retinoids, especially atRA, have attracted initial enthusiasm because of the ability to trigger cancer cell differentiation or apoptosis. However, this therapy exhibited a wide spectrum of toxicity (retinoid toxicity) caused by RARs. The newly identified non-canonical action of atRA, mediated by Crabp1 but not RARs, sheds a new light on an alternative strategy of retinoid therapy. By using Crabp1-selective compounds, it is possible to dampen growth signal in certain cancers without eliciting RAR-mediated retinoid toxicity. In this current study, we indeed have utilized such a compound, C3, to demonstrate a proof-of-concept for this strategy in cell cultures. Further extended studies are needed to validate this strategy.

It is known that Ras, a GTPase, can be activated by RTK activity of EGFR or mutations such as G12V that result in constitutive activity. Ras then binds to the RBD of Raf, which then undergoes a conformational change to adopt the active open structure of Raf kinase domain. This current study, we first focused on the RBD-interaction surface of Crabp1. NMR HSQC analyses reveal that the 6-strand β-sheet surface area of Crabp1 makes direct contact with the RBD. To understand detailed molecular features underlying the competition between Crabp1 and active Ras with regards to Raf regulation, more extensive molecular and structural studies are needed. For instance, it will be important to evaluate conformational changes on the surface of Raf as Crabp1 binds to its RBD, in comparison to the binding of active Ras.

This study provides evidence for a new regulatory mechanism to modulate Raf kinase activation by the action of an endocrine factor, atRA, together with its cytosolic binding protein, Crabp1. Although phosphorylation on S338 (B Raf equivalent S445) is a hallmark of Raf activation, the upstream kinase that targets S338 remains elusive. Studies implicating Pak1, Pak3, Ck2, and other kinases in the upstream signaling of Raf have been observed. But whether or not the activity of these kinases is essential for Raf activation remains controversial. In addition, studies have indicated that Raf itself as a homodimer or heterodimers with other Raf isoforms can also alter S338 phosphorylation. These previous studies underscore the need to further investigate the regulation of Raf activity in various cellular environments or growth conditions.

In this current study we report that Crabp1 may act as a scaffold, or an allosteric regulator, that forms a atRA-inducible complex with at least the MAPK cascade components - RAF, MEK, ERK (Fig. 1C). Interestingly, Crabp1 appears to compete with KSR1, the established scaffold that mediates growth-factor mediated MAPK activation (Fig. 1G) (Kolch 2005). This would suggest that Crabp1 may act by competing with KSR1 for Raf binding, modulating phosphorylation at S338 via the above-mentioned kinases, other Raf molecules, or some unknown upstream kinases. We thus propose a new endocrine (atRA)-elicited mechanism that can also regulate the MAPK kinase pathway and that cross-talks with the canonical growth factor-stimulated MAPK pathway (Fig. 7). Further study is needed to elucidate the particular upstream events that result in Raf activation upon atRA-Crabp1 binding. Nevertheless, our study highlights the increasing complexity of Raf activation mechanisms. Further studies are needed to compare and contrast classical growth-factor activated mechanisms and this novel endocrine (atRA) elicited mechanisms with regards to the regulation of MAPK signaling pathway.

Materials and Methods
Cell Culture and plasmid constructs and transfection. Experimental procedures were conducted according to NIH guidelines and approved by the University of Minnesota Institutional Animal Care and Use Committee. CJ7 (WT) ESCs and CKO ESCs derived from 2.5 day-morula of CKO mice were maintained as described. Briefly, cells were maintained in DMEM medium supplemented with 17% ESC-qualified fetal bovine serum, 2 mM glutamine, 0.1 mM nonessential amino acids, 6 μM β-mercaptoethanol, 2 mM HEPES, and 1,000 U/ml recombinant leukemia inhibitory factor (LIF2005, Sigma-Aldrich, St. Louis, MO). Cells were grown on irradiated mouse embryonic feeder cells in 0.2% (w/v) gelatin-coated plates. Medium was renewed every day. Cells (passage number less than 10) were treated with 100 nM atRA (R2625, Sigma-Aldrich, St. Louis, MO). HEK293T cells were maintained in high glucose DMEM supplemented with 10% (v/v) FBS and 1% (v/v) Penicillin/Streptomycin.

Mouse Crabp1 (NM_013496.3) and Hras (NM_001130443.1) cDNA were cloned into Flag tagged pCMX-PL1, and mouse Braf (NM_139294.5) and Raf1 (NM_01356333.2) were cloned into HA-tagged pCMX-PL1. Mutation (G12V) in Hras was introduced with site-directed mutagenesis kit (Agilent Technologies, Cedar Creek, TX). His-Crabp1 was cloned into pET-15b (69015, Millipore Sigma) to generate N-terminal, His6x-tag. For His-cRaf-(R) fragment, Raf1 aa 51–187 was cloned into a pET-32a vector (69665, Millipore Sigma). Flag-HA-Crabp1 expression lentivirus construct was cloned into pCDH-EF1a-MCS-IRE6-puro (System Biosciences) and prepared as described. Stable clones expressing Flag-HA-Crabp1 and empty vector were established in HEK293T cells using puromycin selection and transfected by routine calcium phosphate method for the reconstitution of MAPK signaling components.

In situ proximity ligation assay. Cells were fixed by 4% (w/v) paraformaldehyde for 10 minutes and permeabilized using 0.2% (v/v) Triton X-100 for 5 minutes at 4 °C. In situ proximity ligation assay was performed using Duolink in situ PLA detection kit (DUO94004, Sigma-Aldrich, St. Louis, MO) according to the protocol provided by the manufacturer. Images were acquired by Olympus FluoView FV1000 BX2 upright confocal microscope at 40x magnification. Antibodies used to detect endogenous complex are against Crabp1 (c1608, Sigma-Aldrich), cRaf (#53745, D4B3J, Cell Signaling, Danvers, MA), Mek1/2 (sc-436, Sant Cruz Biotechnology, 9
Santa Cruz, CA), and p-Erk1/2 (#9101, Cell Signaling). The red fluorescent punctate represents protein complex and images acquired from different fields of individual experiment was counted with ImageJ image processing freeware.

**In vitro kinase assay.**  *Semi in vitro* kinase assay was performed as described. 6 T7 coupled HA-cRaf was synthesized with TnT® Quick Coupled Transcription/Translation System (Promega, Madison, WI). Recombinant unphosphorylated Mek1 (0.4 μg) (14–429, Millipore-Sigma) was incubated with TnT HA-cRaf, 1 μg purified His-Crabp1 in the total volume of 35 μl kinase buffer (20 mM MOPS, pH 7.2, 0.1 mM ATP, 25 mM β-glycerophosphate, 5 mM EGTA, 1 mM sodium orthovanadate, 1 mM DTT, 18 mM MgCl2, and 1x protein inhibitor cocktail) with and without 100 nM atRA for 30 min for 15 min. At the end of the reaction, SDS loading buffer was added and boiled. Mek1 phosphorylation at T286 was detected by western blot.

**In vitro pulldown assay and co-immunoprecipitation.**  TnT HA-tagged Braf and cRaf were incubated with 4.25 μg purified His-Crabp1 and atRA for 30 min in 0.5 ml co-immunoprecipitation (Co-IP) buffer (50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 0.2% (v/v) NP-40, 10% (v/v) glycerol, and 1 mM EDTA) and pulled down with G agarose beads (16–266, Sigma-Aldrich) and anti-HA antibody or normal rabbit IgG at 4°C overnight. After washing, beads were subjected to western blot. For the RBD interaction assay, His-c-Raf(−R) and His-tagged empty plasmid pET-32a (EV) were induced in RosettaTM DE3 host strain. His-c-Raf fragment (aa 51–187) was purified from E. coli cells and TnT Flag-Ras (WT or G12V) following incubation with atRA as above in 0.8 ml of modified Co-IP buffer (50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 10 mM MgCl2, 0.2% (v/v) NP-40, and 10% (v/v) glycerol). For Co-IP experiments, 293T cells were transfected with Flag-HA-Crabp1 only or both myc-c-Raf and Flag-HA-Crabp1 and treated with 100 nM atRA for 15 min. Cell lysates were precipitated with either M2 beads or c-Myc antibody followed by western blot analysis.

**Western blot analysis.**  Whole cell lysates were prepared with RIPA buffer (25 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1% (v/v) NP-40, 1% (w/v) Na-deoxycholate and 1% (w/v) Na-dodecyl sulfate) as described. Antibodies against β-actin (SC-7778), Erk1 (SC-93), and Erk2 (SC-153), His-probe (sc-8036), Ksr1 (SC-515924), CMyc (SC-563643), and HA (sc-7392) were from Santa Cruz Biotechnology. Antibodies against Crabp1 (C1608) and Flag (F3165) were from Millipore Sigma. Antibodies against Mek1 (#12671), p-Mek1 (#9127), Mek2 (#9147), p-Erk1/2 (#9101), p-c-Raf S259 (#9421), and p-c-Raf S383 (#9427) were from Cell Signaling. ARα and hEGF (SRP3027) were from Sigma-Aldrich. Samples were separated on 10% or 13.8% (v/v) SDS polyacrylamide gel, transferred to PVDF membrane, which were cut and probed and re-probed with antibodies to detect protein expression levels, and developed by myECL Imager (Thermo Scientific).

**Protein expression and purification.**  For native Crabp1, RosettaTM DE3 E. coli containing the pET-15b Crabp1 construct was grown in LB + ampicillin (150 μg/mL) at 37°C, 250 rpm until OD600 ~0.6–0.8. Protein expression was then induced with 1 mM IPTG at 25°C, 250 rpm overnight. For 15N and 13C Labeled Crabp1, a single colony from the plate was used to inoculate a 3 ml starter culture in LB media + ampicillin (150 μg/mL) and grown at 37°C, 250 rpm to OD600 ~0.4–0.6. The starter culture was transferred to a 125 ml sterile Erlenmeyer flask containing 25 ml of M9 media + ampicillin (150 μg/mL), containing15NH4Cl and 13C-glucose as the sole source of nitrogen and carbon. 15N Isogro (606871, Sigma-Aldrich) was also supplemented along with 0.5 mg amount of biotin and thiamine. When the OD600 reached ~0.4–0.6, the starter culture was transferred to the fermbach flask containing 1 liter of the same M9 media recipe (see above). Protein was induced with 1 mM IPTG when OD600 reached ~0.8–0.9 for 4 hours at 37°C, 250 rpm. Uniformly 15N labeled Crabp1 was expressed as described without addition of 12C-glucose for titration experiments. Native Crabp1, uniformly 15N, and uniformly 13N 80°C labeled His-tagged Crabp1 was affinity-captured on Ni-NTA beads (Qiagen) and purified in 30 mM Tris-acetate, pH 6.2, 75 mM NaSO4, 10 μM ZnCl2, 1 mM DTT. Concentrated protein was concentrated in NMR buffer (30 mM d1-Tris-d1-acetate, pH 6.2, 75 mM NaSO4, 10 μM ZnCl2, 1 mM TCEP) using Amicon® Ultra-0.5 Centrifugal Filters (UFC5010, Sigma-Aldrich) to 2 mM or 100 μM. For c-Raf(−R) fragment (51–187), His-tagged c-Raf(−R) plasmid was transformed into RosettaTM DE3 E. coli host strain. His-c-Raf fragment (aa 51–187) was purified unlabeled as described above and concentrated to 400 μM. Purified proteins were confirmed by Coomassie blue staining and western blot.

**NMR spectroscopy.**  NMR experiments were performed at 25°C on Bruker Avance III 700, 900-MHz and Avance Neo 600-MHz spectrometer, each equipped with a 5 mM TCI cryoprobe. Spectra were processed using NMRPipe62 and analyzed with Sparky63 and NMRView64. Sequence-specific backbone assignments were completed using three-dimensional spectra, HN(CO)CACB, HNCA, CBCA(CO)NH. Peaks were fully assigned using the NMRFAM-Sparky package65,66 referencing BMRB ID# 19271,12,56. For titration experiments, uniformly 15N-labeled Crabp1 was dissolved at a concentration of 19 μM in 30 mM d1-Tris-d1-acetate, pH 6.2, 75 mM NaSO4, 10 μM ZnCl2, 1 mM DTT, made up using a 95% H2O/5% D2O mixture (v/v). 1H-15N Heteronuclear single quantum coherence (HSQC) NMR spectra were acquired for 15N Crabp1 and increasing amounts of unlabeled His-c-Raf(−R) at 51–197, in the presence and absence of RA (40 μM). Chemical shift differences were calculated as [[(ΔH)] + (0.15A 15N)2]12. Intensity changes (ΔINT) were calculated as (1-INT/INT0). Additional experiments were performed using 19 μM 15N-labeled Crabp1 +/− 21 μM RA +/− 126 μM c-Raf(−R).
**Statistical analysis.** Band intensities were determined by densitometric scanning using ImageJ, and relative fold intensities are numerically marked under each relevant panel. Comparisons between groups were evaluated with Student’s t-test. Differences were considered significant at P < 0.05. All values are presented as mean ± SEM.

**References**

1. Duester, G. Retinoic acid synthesis and signaling during early organogenesis. *Cell* **134**, 921–31 (2008).
2. Germain, P. et al. International Union of Pharmacology. LX. Retinoic Acid Receptors. *Pharmacol. Rev.* **58**, 712–725 (2006).
3. Samarat, E. & Rochette-Egly, C. Nuclear retinoic acid receptors: conduits of the retinoic acid signaling during development. *Mol. Cell. Endocrinol.* **348**, 348–360 (2012).
4. Wei, L.-N. Retinoid Receptors and Their Coregulators. *Annu. Rev. Pharmacol. Toxicol.* **43**, 47–72 (2003).
5. Masiá, S., Álvarez, S., de Lera, A. R. & Barettino, D. Rapid, nonmammalian actions of retinoic acid on phosphatidylinositol-1-kinase signaling pathway mediated by the retinoic acid receptor. *Mol. Endocrinol.* **21**, 2391–402 (2007).
6. Chen, N. & Napoli, J. L. All-trans-retinoic acid stimulates translation and induces spine formation in hippocampal neurons through a membrane-associated RARexs. *FASEB J.* **22**, 236–245 (2008).
7. Rochette-Egly, C. Retinoic acid signaling and mouse embryonic stem cell differentiation: Cross talk between genomic and non-genomic effects of RA. *Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids* **1851**, 66–75 (2015).
8. Persaud, S. D., Lin, Y. W., Wu, C. Y., Kagaychika, H. & Wei, L. N. Cellular retinoic acid binding protein I mediates rapid non-canonical activation of ERK1/2 by all-trans retinoic acid. *Cell Signal* **25**, 19–25 (2013).
9. Persaud, S. D. et al. All-trans-retinoic acid analogs promote cancer cell apoptosis through non-genomic Crabp1 mediating ERK1/2 phosphorylation. *Sci Rep* **6**, 22396 (2016).
10. Lin, Y. L., Persaud, S. D., Nieuw, J. & Wei, L. N. Cellular Retinoic Acid-Binding Protein 1 Modulates Stem Cell Proliferation to Affect Learning and Memory in Male Mice. *Endocrinology* **158**, 3004–3014 (2017).
11. Wortzel, I. & Seger, R. The ERK cascade: Distinct functions within various subcellular organelles. *Genes and Cancer* **2**, 195–209 (2011).
12. Cargnello, M. & Roux, P. P. Activation and Function of the MAPKs and Their Substrates, the MAPK-Activated Protein Kinases. *Microbiol. Mol. Biol. Rev.* **75**, 50–83 (2011).
13. Roskoski, R. Jr. RAF protein-serine/threonine kinases: structure and regulation. *Biochem. Biophys. Res. Commun.* **399**, 313–317 (2010).
14. Roskoski, R. Jr. ERK1/2 MAP kinases: Structure, function, and regulation. *Pharmacol Res* **66**, 105–143 (2012).
15. Martinelli, E., Morgillo, F., Trotani, T. & Ciardiello, F. Cancer resistance to therapies against the EGFR-RAS-RAF pathway: The role of MEK. *Cancer Treat Rev* **53**, 61–69 (2017).
16. Lavone, H. & Thirrien, M. Regulation of RAF protein kinases in ERK signalling. *Nat Rev Mol Cell Biol* **16**, 281–298 (2015).
17. Smith, E. F. et al. AKAP-Lbc enhances cyclic AMP control of the ERK1/2 cascade. *Nat. Cell Biol.* **12**, 1242–1249 (2010).
18. Castellano, E. & Santos, E. Functional specificity of ras isoforms: so similar but so different. *Genes Cancer* **2**, 216–231 (2011).
19. Cox, A. D., Festik, S. W., Kimmelman, A. C., Luo, J. & Der, C. J. Drugging the undruggable RAS: Mission possible? *Nat Rev Drug Discov* **13**, 828–851 (2014).
20. Papke, B. & Der, C. J. Drugging RAS: Know the enemy. *British Journal of Cancer* **114**, 643–655 (2016).
21. Prior, I. A., Lewis, P. D. & Mattos, C. A comprehensive survey of Ras mutations in cancer. *Cancer Res* **72**, 2457–2467 (2012).
22. Matallanas, D. et al. Raf family kinases: old dogs have learned new tricks. *Genes Cancer* **2**, 232–260 (2011).
23. Dong, D., Ruuska, S. E., Levinthal, D. J. & Noy, N. Distinct roles for cellular retinoic acid-binding proteins I and II in regulating signaling by retinoic acid. *J Biol Chem* **274**, 23685–23698 (1999).
24. Budyak, I. L., Zhravleva, A. & Gierasch, L. M. The Role of Aromatic-Aromatic Interactions in Strand-Strand Stabilization of beta-Sheets. *J Mol Biol* **425**, 3522–3535 (2013).
25. Chaudhuri, B. N. et al. Structures of cellular retinoic acid binding proteins I and II in complex with synthetic retinoids. *Acta Crystallogr D Biol Crystallogr* **55**, 1850–1857 (1999).
26. Kleywegt, G. J. et al. Crystal structures of rat retinoic acid binding proteins I and II in complex with all-trans-retinoic acid and a synthetic retinoid. *Structure* **2**, 1241–1258 (1994).
27. Napoli, J. L. Cellular retinoid binding-proteins. CRBP, CRABP, FABP: Effects on retinoid metabolism, function and related diseases. *Pharmacol Ther* **173**, 19–33 (2017).
28. Keeler, J. Understanding NMR spectroscopy. (John Wiley & Sons, 2011).
29. Ong, D. E. & Chytil, F. Retinoid acid-binding protein in rat tissue. Partial purification and comparison to rat tissue retinol-binding protein. *J Biol Chem* **250**, 6113–6117 (1975).
30. Ong, D. E. & Chytil, F. Cellular retinoic acid-binding protein from rat testis. Purification and characterization. *J. Biol. Chem.* **253**, 4551–4 (1978).
31. Thompson, J. R., Bratt, J. M. & Banaszak, L. J. Crystal structure of cellular retinoic acid binding protein I shows increased access to the binding cavity due to formation of an intermolecular beta-sheet. *J Mol Biol* **252**, 433–446 (1995).
32. Higo, I., Liu, Z. P. & Gierasch, L. M. 1H and 15N resonance assignments and secondary structure of cellular retinoic acid-binding protein with and without bound ligand. *J Biol Chem* **274**, 741–760 (1999).
33. Cheepala, S. B. et al. Identification of the B-Raf/Mek/Erk MAP kinase pathway as a target for all-trans retinoic acid during skin cancer promotion. *Mol. Cancer* **8**, 27 (2009).
34. Greci, G., Schiffmann, I. & Libbret, M. Epigenetic priming of non-small cell lung cancer cells to the antiproliferative and differentiating effects of all-trans retinoic acid. *J Cancer Res Clin Oncol* **141**, 2171–2180 (2015).
35. Zhang, L. M. et al. All-trans retinoic acid induces cell-cycle arrest in human cutaneous squamous carcinoma cells by inhibiting the mitogen-activated protein kinase-activated protein 1 pathway. *Clin. Exp. Dermatol.* **39**, 354–360 (2014).
36. Park, S. W. et al. CRABP1 protects the heart from isoproterenol-induced acute and chronic remodeling. *J. Endocrinol.* **236**, 151–165 (2018).
37. Achari-Divakar, S. K. et al. A Small Molecule RAS-Mimetic Disrupts RAS Association with Effector Proteins to Block Signaling. *Cell* **165**, 643–655 (2016).
38. Aggarwal, S. et al. Nonclassical Action of Retinoic Acid on the Activation of the cAMP Response Element-binding Protein in Normal Human Bronchial Epithelial Cells. *Mol. Biol. Cell* **17**, 566–575 (2005).
39. Sapio, J. M., Monks, T. J. & Lau, S. S. All-trans-retinoic acid-mediated cytoprotection in LLC-PK1 renal epithelial cells is coupled to Erk activation in a ROS-independent manner. *Am. J. Physiol. Cell Physiol.* **313**, F1200–F1208 (2017).
40. Zhang, S. et al. All-trans retinoic acid inhibits the proliferation of SGC7901 cells by regulating cavelin-1 localization via the ERK/ MAPK signaling pathway. *OncoLett.* **15**, 1523–1528 (2018).
41. Evans, T. R. J. & Kaye, S. B. Retinoids: Present role and future potential. *British Journal of Cancer* **80**, 1–8 (1999).
42. Niles, R. M. Signaling pathways in retinoid chemoprevention and treatment of cancer. *Mutat. Res.* **555**, 81–96 (2004).
43. de Lera, A. R., Bourguet, W., Altucci, L. & Gronemeyer, H. Design of selective nuclear receptor modulators: RAR and RXR as a case study. *Nature Reviews Drug Discovery* **6**, 811–820 (2007).
44. Coles, L. C. & Shaw, P. E. PAK1 primes MEK1 for phosphorylation by Raf-1 kinase during cross-cascade activation of the ERK pathway. *Oncogene* **21**, 2236–2244 (2002).
45. Chilochees, A., Mason, C. S. & Marais, R. S338 Phosphorylation of Raf-1 Is Independent of Phosphatidylinositol 3-Kinase and Pak3. Mol. Cell. Biol. 21, 2423–2434 (2002).
46. Ritt, D. A. et al. CK2 Is a Component of the KSR1 Scaffold Complex that Contributes to Raf Kinase Activation. Curr. Biol. 17, 179–184 (2007).
47. Salzano, M. et al. Calcium/calmodulin-dependent protein kinase II (CaMKII) phosphorylates Raf-1 at serine 338 and mediates Ras-stimulated Raf-1 activation. Cell Cycle 11, 2100–2106 (2012).
48. Hu, J. et al. Allosteric activation of functionally asymmetric RAF kinase dimers. Cell 154, 1036–1046 (2013).
49. Chuang, Y. S. et al. Promyelocytic leukemia protein in retinoic acid-induced chromatin remodeling of Oct4 gene promoter. Stem Cells 29, 660–669 (2011).
50. Ho, P.-C. et al. Modulation of lysine acetylation-stimulated repressive activity by Erk2-mediated phosphorylation of RIP140 in adipocyte differentiation. Cell. Signal. 20, 1911–9 (2008).
51. Lee, B. et al. RIP140 in monocytes/macrophages regulates osteoclast differentiation and bone homeostasis. JCI Insight 2, e90517 (2017).
52. Delaglio, F. et al. NMRPipe: a multidimensional spectral processing system based on UNIX pipes. J Biomol NMR 6, 277–293 (1995).
53. Lee, W., Tonelli, M. & Markley, J. L. NMRFAM-SPARKY: enhanced software for biomolecular NMR spectroscopy. Bioinformatics 31, 1323–1327 (2015).
54. Johnson, B. A. & Blevins, R. A. NMR View: A computer program for the visualization and analysis of NMR data. J Biomol NMR 4, 603–614 (1994).
55. Bahrami, A., Assadi, A. H., Markley, J. L. & Eghbalnia, H. R. Probabilistic interaction network of evidence algorithm and its application to complete labeling of peak lists from protein NMR spectroscopy. PLoS Comput Biol 5, e1000307 (2009).
56. Ulriche, K., Sanders, M., Grinberg, F., Galvosas, F. & Vasekov, S. Application of pulsed field gradient NMR with high gradient strength for studies of self-diffusion in lipid membranes on the nanoscale. Langmuir 24, 7365–7370 (2008).

Acknowledgements
This work was supported by DK54733, DK60521, Dean’s Commitment, and the Distinguished McKnight Professorship of University of Minnesota to LNW. Data were collected at the Minnesota NMR Center, University of Minnesota. Funding for NMR instrumentation was provided by the Office of the Vice President for Research, the Medical School, the College of Biological Science, NIH, NSF, and the Minnesota Medical Foundation.

Author Contributions
S.W.P., J.N., S.D.P., Y.X., M.C.M., K.H.M. and L.-N.W. designed research; S.W.P., S.D.P., J.N., M.C.M., Y.X., Y.W.L. and Y.-L.L. performed research; L.-N.W. contributed new reagents/tools; H.K. provided compounds; S.W.P., S.D.P., J.N., M.C.M., K.H.M. and L.-N.W. analyzed data; and S.W.P., S.D.P., J.N., K.H.M. and L.-N.W. wrote the paper. L.N.W. is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Additional Information
Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-019-47354-7.

Competing Interests: The authors declare no competing interests.

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2019